ReviewCVIR endovascular2026
Embolization therapy for pelvic arteriovenous malformations: a systematic review.
Review in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A pelvic arteriovenous malformation (AVM) is a rare congenital vascular anomaly that may cause relevant clinical symptoms. This systematic review synthesizes current evidence on diagnostic approaches, embolization techniques, and clinical outcomes for pelvic AVMs. A PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses)-compliant literature search identified 19 studies comprising 49 patients treated with embolization therapy. Venous approaches, including direct puncture of a dominant outflow vein (DOV), were most commonly performed. Coils were the primary embolic agent, frequently combined with adjunctive materials, reflecting substantial technical heterogeneity. Despite this variability, embolization achieved consistently high technical and clinical success rates with low complication rates over a mean follow-up of 21.1 months. Embolization therapy of DOV may be considered as first-line therapy for symptomatic pelvic AVMs, although future comparative studies are needed to guide standardized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.